Page not found
Search results
-
Versatile C. difficile blocker
01/26/2018 Clostridium difficile (C. difficile) infection is the leading cause of hospital-acquired ... is common and new therapies are needed. TcdB is a toxin produced by the bacterium that upon entering epithelial cells lining the ...
sommers - 01/30/2018 - 2:45pm
-
Tech Connect, Vol. 6, Issue 6: VEN kicks off entrepreneurial education series
... License Agreement with a large biotechnology company for a mouse model developed by Raymond Harris in the School of Medicine. ... alternative career paths while also providing educational content about those fields of work. This session will cover an overview ...
steelmk - 11/15/2016 - 4:17pm
-
Tech Connect, Vol. 7, Issue 5: New study shows Play Nicely™ program is an effective positive parenting strategy
... The project is now exploiting an antisense microRNA (anti-miR) therapeutic strategy directed to the inhibition of either one or two ... opportunities with an international diagnostics company for Clostridium difficile antibodies created by Borden Lacy, of the Department of ...
steelmk - 11/15/2016 - 2:29pm
-
Tech Connect, Vol. 7, Issue 7: CTTC welcomes UASP Fellow Tonny Omwansa
... invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities. ... a materials license for Clostridium difficile research reagents developed by Borden Lacy of the ...
steelmk - 11/10/2016 - 7:45am
-
Novel Targets Involved in Ferroptosis for Therapeutic Development in Oncology
... Cumulus Oncology is developing anti‑cancer therapies for clinical settings in areas of high unmet need, ...
cttc_admin - 03/14/2024 - 6:11pm
-
Partnership to help bring Zika virus therapy to clinic
... Initially Batavia will deploy the system to produce the anti-Zika antibody in collaboration with VUMC and IDBiologics, which is using a ... the isolation of a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. Dubbed ...
sommers - 09/20/2019 - 2:07pm
-
Tech Connect, Vol. 6, Issue 7: Collaboration seeks to develop new therapies for bone and other diseases
... pharmaceutical company regarding their interest in anti-cancer compounds under development at Vanderbilt. Attended ... alternative career paths while also providing educational content about those fields of work. This session will cover an overview ...
steelmk - 11/15/2016 - 4:11pm
-
Early study finds antibody that ‘neutralizes’ Zika virus
... Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. The ... The findings may also aid efforts to develop an effective anti-Zika vaccine, said James Crowe Jr., M.D., director of the Vanderbilt ...
steelmk - 11/08/2016 - 2:00pm
-
Twelve at Vanderbilt are among world’s highly cited researchers
... the development of new vaccines and therapeutics, including monoclonal antibodies, to treat and prevent viral disease. De-en Jiang , ... shedding light on inflammatory diseases like lupus and on anti-tumor immunity. Dan Roden , MD, holder of the Sam L. Clark, MD, PhD ...
sommers - 11/20/2023 - 8:59am
-
Targeted photodynamic therapy for S. aureus infections
... treat MRSA infections. First, the patient receives 1) a monoclonal antibody that is conjugated to a near-infrared photosensitizer and ... of S. aureus infections. Bottom : in vivo mouse model demonstrates effective treatment of luminescent MRSA skin ...
cttc_admin - 10/31/2023 - 10:59am